Hydrogen-Rich Celsior Solution — Competitive Intelligence Brief

Hydrogen-Rich Celsior Solution (Hydrogen-Rich Celsior Solution) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Organ preservation solution. Area: Transplantation/Organ Preservation.

phase 3 Organ preservation solution Reactive oxygen species (ROS), particularly hydroxyl radicals Transplantation/Organ Preservation Small molecule

Target snapshot

Hydrogen-Rich Celsior Solution (Hydrogen-Rich Celsior Solution) — RenJi Hospital. Hydrogen-rich Celsior solution reduces ischemic reperfusion injury by providing antioxidant protection through molecular hydrogen during organ preservation and transplantation.

Comparator set (4 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hydrogen-Rich Celsior Solution TARGET	Hydrogen-Rich Celsior Solution	RenJi Hospital	phase 3	Organ preservation solution	Reactive oxygen species (ROS), particularly hydroxyl radicals
HTK Custodiol	HTK Custodiol	Rigshospitalet, Denmark	marketed	Organ preservation solution
Custodiol Htk Soln	Custodiol Htk Soln	Lourdes Montero Cruces	marketed	Organ preservation solution
Custodiol-N	Custodiol-N	Dr. F. Köhler Chemie GmbH	phase 3	Organ preservation solution
Custodiol HTK	Custodiol HTK	Marc Sakwa, MD	phase 3	Organ preservation solution

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Organ preservation solution class)

1. Dr. F. Köhler Chemie GmbH · 1 drug in this class
2. Lourdes Montero Cruces · 1 drug in this class
3. Marc Sakwa, MD · 1 drug in this class
4. RenJi Hospital · 1 drug in this class
5. Rigshospitalet, Denmark · 1 drug in this class